Organon & Co. research snapshot
OGN AI stock analysis currently reads Organon & Co. as a specialty pharmaceutical company focused on women health, biosimilars, and established brands. At the July 12, 2026 data cutoff, OGN traded near $13.52 with an implied market capitalization of about $3.55 billion. The stock has rallied sharply from its $5.69 March 2026 low, driven by pipeline catalysts including MIUDELLA, TOFIDENCE, and expanded biosimilar agreements. The positive case depends on new product revenue growth, margin recovery, and debt reduction. The risk case centers on high leverage, litigation exposure, generic competition, and execution risk across a dispersed brand portfolio. This page is informational research, not investment advice.
Current price
$13.52
Market cap
$3.55 billion
AI score
62 / 100
Rating
Turnaround pharma with biosimilar pipeline upside and high debt
Trend status
Strong uptrend from 52-week low near YTD +89%
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Organon sells women health products, biosimilars, and legacy established brands across contraception, fertility, immunology, oncology, cardiovascular, and respiratory categories. | Medium |
| Moat | The moat comes from long-standing brand recognition in women health, manufacturing know-how for contraceptive devices like Nexplanon and NuvaRing, biosimilar regulatory pathways, and a global commercial infrastructure inherited from Merck. | Low-medium |
| Management | CEO Kevin Ali leads with a strategy of biosimilar expansion, in-licensing women health innovations (MIUDELLA IUD), and geographic diversification, while managing a high-debt balance sheet from the Merck spin-off. | Medium |
| Financial trend | FY2025 revenue was about $6.22 billion. Q1 2026 revenue was $1.46 billion. GAAP net income has been volatile with impairment and acquisition charges. Free cash flow has remained positive but variable. | Medium-high |
| Valuation | At $13.52, OGN traded near 14.5x TTM GAAP EPS, 6.7x TTM free cash flow, 3.9x book value, and EV/EBITDA near 7.9x. The single-digit P/FCF ratio reflects low market confidence in earnings durability. | Medium-high |
| Technical trend | The stock was in a strong uptrend from the $5.69 March low, trading near its 52-week high of $13.60 with elevated YTD returns of about 89%. Short-term momentum is positive but the move has been very rapid. | Medium |
| Risk level | The biggest risks are the high debt-to-equity ratio (~949%), litigation related to Zantac and talc claims, generic competition to established brands, biosimilar pricing pressure, losses in certain therapeutic categories, and key-person risk for a recently independent company. | Medium-high |
| AI confidence | Medium-high for descriptive research and arithmetic checks. Lower for exact stock outcomes because small-cap pharma stocks can reprice sharply around product approvals, litigation rulings, earnings, and debt refinancing events. | Medium-high data |
| Investment certainty | Low-medium certainty. Organon is executing a turnaround and biosimilar build, but the high debt, short track record, and competitive pressure on legacy brands make a buy decision contingent on confidence in cash flow durability. | Low-medium |
OGN AI stock forecast
The OGN AI stock forecast uses scenario math around the $13.52 quote and normalized EPS of about $1.10 as a base. The audited three-year framework produced a bearish area near $12, a base area near $19, and a bullish area near $30 before dividends.
$27 to $33
More likely if MIUDELLA and biosimilar pipeline (TOFIDENCE, PYZCHIVA) ramp faster, women health margins improve, the company reduces debt meaningfully, and investors apply a high-teens earnings multiple reflecting improved growth and credit profile.
$17 to $21
More likely if normalized EPS grows in the high single digits, biosimilars and women health products deliver steady growth, established brand erosion is gradual, and the market applies a low-to-mid-teens earnings multiple.
$10 to $14
More likely if biosimilar pricing pressure intensifies, litigation creates material liability, generic competition accelerates for legacy brands, debt servicing constrains investment, or the market applies a single-digit earnings multiple.
OGN AI technical analysis
OGN AI technical analysis showed strong momentum as of the July 12, 2026 cutoff. OGN was trading near $13.52, just below the 52-week high of $13.60 set in the same week. The stock has rallied approximately 138% from the $5.69 March 2026 low. Momentum indicators were elevated, suggesting the move has been rapid and may need consolidation.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $13.52 | Quote snapshot used for market cap math at the July 12, 2026 cutoff. |
| Near support | $12.00 to $12.50 | The area around prior resistance-turned-support from May-June 2026 consolidation. |
| Near resistance | $13.60 to $14.00 | The 52-week high near $13.60 is immediate resistance, followed by the round $14 level. |
| 52-week low | $5.69 | Set on March 30, 2026. The stock more than doubled from this low in just over three months. |
| Momentum | RSI likely above 70 | After a 138% rally in about 3.5 months, short-term momentum readings were likely in overbought territory. |
| Volume | About 2.9 million recent shares | Yahoo Finance reported July 10 volume at 2.87M, below the 50-day average of 7.68M, suggesting some exhaustion after the rally. |
| Volatility | High beta small-cap pharma volatility | Beta of 1.54 (5Y) and 2.57 (1Y) implies amplified moves relative to the broader market. |
| Invalidation | Close below $11.00, then $9.00 | A decisive break below $12 support would weaken the setup. A close below $9 would suggest the uptrend has failed. |
OGN AI trading strategy
The OGN AI trading strategy is a rules-based research framework for a small-cap pharma stock with very strong near-term momentum, high beta, and significant fundamental risk from debt and litigation. It is not personal advice and should be paired with live quotes, earnings calendar, and position sizing rules.
Watch for OGN to consolidate above $13 and establish volume support before extending. A pullback toward $12 to $12.50 with declining volume could offer a lower-risk entry if the fundamental thesis remains intact.
A close below $12 or a broken moving average after earnings, litigation news, or product data should invalidate the trend-following setup.
If OGN pulls back sharply from resistance on high volume without fundamental damage, compare the selloff with cash flow, product pipeline momentum, and debt reduction trajectory before considering re-entry.
Do not average down because small-cap pharma can gap down on litigation or trial outcomes, and high leverage amplifies downside risk.
Track MIUDELLA launch revenue, biosimilar approvals (TOFIDENCE, PYZCHIVA, Hadlima), Nexplanon/NuvaRing trends, established brand erosion, litigation developments, debt reduction, free cash flow conversion, and Q2 2026 earnings.
Reduce exposure if revenue growth comes mainly from price or one-time items rather than volume from new products, or if debt maturities become a refinancing risk.
Investment research summary
Organon delivers prescription therapies and medical devices across women health (contraception, fertility, postpartum hemorrhage), biosimilars (immunology, oncology, bone health), and established brands (cardiovascular, respiratory, dermatology, pain management) to a global customer base.
The moat is moderate in women health where brands like Nexplanon have strong physician and patient loyalty, and in biosimilars where regulatory barriers and manufacturing expertise provide some protection. The moat narrows when generics enter established brands or larger competitors launch competing biosimilars.
The thesis fails if biosimilar pricing and volume disappoint, MIUDELLA and pipeline products underperform, established brand erosion outpaces new product growth, litigation (Zantac, talc) creates material liability, or the high debt balance sheet restricts strategic flexibility.
Kevin Ali became CEO in 2021 after the Merck spin-off. Management is building a focused women health and biosimilar company through in-licensing, biosimilar partnerships (Samsung Bioepis, Henlius), and geographic expansion, while managing a leveraged balance sheet.
Pharma benefits from aging demographics, chronic disease prevalence, and increasing biosimilar adoption globally, but faces payer price pressure, generic competition, regulatory scrutiny, patent expirations, and litigation risks across multiple product categories.
OGN trades at a discount to large-cap pharma peers on P/E and P/FCF, reflecting its high leverage, short track record, and execution risk. Margin of safety depends on whether new product revenue and debt reduction can offset established brand erosion and litigation overhang.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| OGN price | $13.52 | Yahoo Finance and TradingView quote snapshots | July 12, 2026 |
| Market capitalization | $3.55 billion, verified as $13.52 x 262.6 million shares | financial_rigor.py market cap verification | July 12, 2026 |
| Shares outstanding | ~262.6 million, cross-checked against TradingView 261.64 million float | Yahoo Finance and TradingView | July 12, 2026 |
| TTM reported revenue | $6.19 billion (consensus of Yahoo $6.16B and TradingView $6.22B) | Yahoo Finance and TradingView | July 12, 2026 |
| TTM net income | Yahoo reports $246M (available to common). TradingView reports $187M (FY) | Yahoo Finance and TradingView | July 12, 2026 |
| TTM levered free cash flow | About $529 million | Yahoo Finance cash flow statement | July 12, 2026 |
| Cash and short-term investments | $1.12 billion | Yahoo Finance balance sheet (mrq) | July 12, 2026 |
| Enterprise value | $11.00 billion | Yahoo Finance key statistics | July 12, 2026 |
| Total debt / Equity | 949% debt-to-equity ratio | Yahoo Finance | July 12, 2026 |
| Q1 2026 revenue and net income | $1.46 billion revenue, $146 million net income | Yahoo Finance earnings data | July 12, 2026 |
| 52-week price range | $5.69 to $13.60 | TradingView and Yahoo Finance | July 12, 2026 |
| Technical indicators | Stock near 52-week high after 138% rally from March low. RSI likely overbought after rapid move. | TradingView technical summary | July 12, 2026 |
This OGN AI stock analysis is an informational research tool only. It is not investment advice, a recommendation to buy or sell Organon & Co., or a guarantee of future returns. Forecast scenarios are based on available public data as of July 12, 2026 and can be wrong if fundamentals, valuation, litigation, product approvals, regulation, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
